Vitrafy Life Sciences Partners With Vitalant Innovation Center on Red Blood Cell Preservation Technology

MT Newswires Live
Jun 02

Vitrafy Life Sciences (ASX:VFY) has partnered with US healthcare organization Vitalant Innovation Center to address a "looming crisis" for red blood cell preservation, according to a Tuesday filing with the Australian bourse.

The companies aim to configure Vitrafy's cryopreservation ecosystem as a successor to legacy technology and products that will be discontinued from 2027, which poses a threat to red blood cell stockpiles, per the filing.

To support that objective, Vitrafy will initially place two cryopreservation freezing units at the Vitalant Innovation Center in Denver. The placement will not generate revenue, but the company expects the collaboration "to support broader market and government engagement toward a unified response," it said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10